Zhang Xian, Liu Yang, Tang Hua-Fei, Jiang Feng, Chen Chun-Liang, Wang Ting-Ting, Gu Hui-Zhong, Zhao Qiang, Ma Rui
Department of Pharmacy, The 305 Hospital of People's Liberation Army, Beijing 100017, China.
World J Psychiatry. 2024 Sep 19;14(9):1354-1363. doi: 10.5498/wjp.v14.i9.1354.
To assess the effectiveness of Shugan Jieyu capsules on peripheral blood miR-124, miR-132, and brain-derived neurotrophic factor (BDNF) levels in patients with mild to moderate depression following coronary artery intervention [percutaneous coronary intervention (PCI)] for coronary heart disease.
To evaluate the therapeutic efficacy of Shugan Jieyu capsules and their effects on the peripheral blood levels of miR-124, miR-132, and BDNF in patients with mild to moderate depression following PCI for coronary heart disease.
Patients with mild-to-moderate depression of the liver-qi stagnation type after PCI for coronary heart disease at the 305 Hospital of the People's Liberation Army were enrolled from June 2022 to November 2023 and randomly assigned to two groups: Experimental (treated with Shugan Jieyu capsules) and control (treated with escitalopram oxalate tablets). This study compared the antidepressant effects of these treatments using 17-item Hamilton Rating Scale for Depression (HAMD-17) scores, metabolic equivalents, low-density lipoprotein cholesterol, BDNF, high-sensitivity C-reactive protein levels, miR-124 and miR-132 levels, distribution of immune-related lymphocyte subsets, and traditional Chinese medicine syndrome scores before and after 6 weeks of treatment.
No significant difference was observed in any index between the two groups before treatment ( > 0.05). After treatment, the total efficacy rates were 93.33% and 90.00% in the experimental and control groups, respectively. Experimental group had significantly lower scores for the main and secondary syndromes compared to the control group ( < 0.05). No significant difference was observed in the metabolic equivalents between the two groups before and after treatment ( > 0.05). The levels of low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and miR-132 were significantly lower, whereas those of miR-124, BDNF, CD3+T lymphocytes, CD3+CD4+T helper lymphocytes, and CD3+CD4+/CD3+CD8+ cells were significantly higher in the experimental group compared to the control group ( < 0.05). The incidence of adverse reactions during experimental group was significantly lower than that in control group ( < 0.05).
Shugan Jieyu capsules have good efficacy in patients with mild-to-moderate depression after PCI, and its mechanism may contribute to the regulation of miR-124, miR-132, BDNF levels, and lymphoid immune cells.
评估疏肝解郁胶囊对冠心病冠状动脉介入治疗（经皮冠状动脉介入术，PCI）后轻中度抑郁症患者外周血miR - 124、miR - 132及脑源性神经营养因子（BDNF）水平的影响。
评价疏肝解郁胶囊对冠心病PCI术后轻中度抑郁症患者的治疗效果及其对外周血miR - 124、miR - 132及BDNF水平的影响。
选取2022年6月至2023年11月解放军第305医院冠心病PCI术后肝郁气滞型轻中度抑郁症患者，随机分为两组：试验组（服用疏肝解郁胶囊）和对照组（服用草酸艾司西酞普兰片）。本研究采用17项汉密尔顿抑郁量表（HAMD - 17）评分、代谢当量、低密度脂蛋白胆固醇、BDNF、高敏C反应蛋白水平、miR - 124和miR - 132水平、免疫相关淋巴细胞亚群分布及中医证候评分，比较治疗6周前后这些治疗方法的抗抑郁效果。
治疗前两组各项指标比较，差异均无统计学意义（>0.05）。治疗后，试验组和对照组的总有效率分别为93.33%和90.00%。试验组主症和次症评分均显著低于对照组（<0.05）。治疗前后两组代谢当量比较，差异无统计学意义（>0.05）。试验组低密度脂蛋白胆固醇、高敏C反应蛋白和miR - 132水平显著低于对照组，而miR - 124、BDNF、CD3⁺T淋巴细胞、CD3⁺CD4⁺辅助性T淋巴细胞及CD3⁺CD4⁺/CD3⁺CD8⁺细胞水平显著高于对照组（<0.05）。试验组不良反应发生率显著低于对照组（<0.05）。
疏肝解郁胶囊对PCI术后轻中度抑郁症患者有良好疗效，其机制可能与调节miR - 124、miR - 132、BDNF水平及淋巴细胞免疫有关。
